Analyst Ratings for PTC Therapeutics
Analysts have provided the following ratings for PTC Therapeutics (NASDAQ:PTCT) within the last quarter:
Citigroup Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $70
Citigroup analyst David Lebowitz initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $70.
Raymond James Maintains Outperform on PTC Therapeutics, Raises Price Target to $60
Raymond James analyst Danielle Brill maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target from $55 to $60.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
ClearPoint Neuro Congratulates Partner PTC Therapeutics On Being Granted Marketing Authorization By The European Commission For Upstaza – First Disease-Modifying Treatment For AADC Deficiency
ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, congratulates partner PTC Therapeutics for being granted
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
